Japanese CAD patients get continued access to experimental drug sutimlimab
NCT ID NCT05132127
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study gave sutimlimab to 7 adults in Japan with cold agglutinin disease (CAD) who had already completed earlier trials and still needed treatment. The goal was to monitor safety and side effects over time until the drug became commercially available. It is a small, open-label study focused on long-term safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sutimlimab
What this could lead to
If successful, this could confirm sutimlimab as a safe long-term treatment option for cold agglutinin disease in Japan.
What could go wrong
This is a small, open-label study with only 7 participants, so results may not apply broadly. It focuses on safety, not effectiveness, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLD AGGLUTININ DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 3920001
Tokyo, 113-8431, Japan
-
Investigational Site Number 3920002
Saitama, 350-0495, Japan
-
Investigational Site Number 3920003
Osaka, 565-0871, Japan
-
Investigational Site Number 3920004
Kanagawa, 259-1193, Japan
-
Investigational Site Number 3920005
Ishikawa, 920-8530, Japan